Video

Conclusion: Addressing Unmet Needs in Lung Cancer

For High-Definition, Click

In the final segment of the discussion, panelists provide their finals on thoughts on emerging areas in the treatment of lung cancer.

View the video, to hear each experts insight!

Related Videos
Eunice S. Wang, MD
Marcella Ali Kaddoura, MD
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.
Cedric Pobel, MD
Related Content
FDA
December 9th 2024

FDA Grants Breakthrough Therapy Designation to Dato-DXd for Previously Treated EGFR+ Advanced NSCLC

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
October 30th 2024

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

Roy S. Herbst, MD, PhD
December 5th 2024

Immunotherapy Reshapes Perioperative Strategies for Early NSCLC Without Driver Mutations

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

FDA
December 4th 2024

FDA Grants Accelerated Approval to Zenocutuzumab for NRG1+ NSCLC and Pancreatic Adenocarcinoma

Francisco J. Esteva, MD, PhD
December 4th 2024

NGS and Novel Therapies Lends to Prolonged Survival Outcomes in HR+/ HER2– Breast Cancer